ISSUE BRIEF

The Peptide Vote Heard Round the Compounding World

What the July 2026 PCAC Meeting Means, and How Fast the FDA Could Move If It Wanted To

The Peptide Vote Heard Round the Compounding World

What the July 2026 PCAC Meetings Mean, and How Fast the FDA Could Move If It Wanted To

Something happened in Silver Spring this week that a lot of people in the compounding world thought they would never see. On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) sat down to consider seven peptides for the section 503A bulk drug substances list. Those seven were BPC-157, KPV, TB-500, MOTS-C, Emideltide (also known as DSIP), Semax, and Epitalon. By the time the meeting ended, six of the seven had earned an affirmative recommendation. But only a recommendation.

That is not a typo. Six of seven.

For anyone who has watched this committee, the result is remarkable. The FDA’s own career civil servants had recommended against all seven, citing incomplete chemical characterization, thin human clinical data, and immunogenicity concerns. All of which, the representatives from the United States Native American Communities reminded the committee were solvable. The committee listened, deliberated, and then voted to recommend inclusion anyway. BPC-157 passed by a margin of 8-6 with one abstention, and KPV, TB-500, MOTS-C, Semax, and Epitalon followed suit. Only Emideltide fell short, and just barely, on a 7-6 vote.

A committee that actually looked like the field it regulates

Contrast this week with the last time PCAC took up substances of this kind. When the committee considered nominations such as ipamorelin and kisspeptin-10, which are peptides in substance if not in branding, it returned no affirmative votes. Not one. Every nominated substance was turned away.

What changed? In a word: balance. The earlier committee was weighted heavily toward academic and research voices, with little representation from the clinicians and pharmacists who actually prescribe and dispense these products and watch how patients respond to them. The committee that met this week was far better balanced. It included members drawn from the practice of medicine and the realities of patient care. These are people who understand peptide therapy not as an abstraction in a briefing document, but as something patients are already using every day.

Critics have been quick to point out that some of the new members have professional ties to the peptide space, and that criticism deserves a fair hearing. But so does the point on the other side. A committee composed almost entirely of people with no practical exposure to the substances it evaluates is not “neutral.” It is simply blind in a different direction. A genuinely well-balanced committee hears from both the laboratory bench and the clinical exam room. The previous PCAC panels heard mostly from the laboratory bench and voted accordingly. This one heard from both, and the votes reflect it.

But a “yes” vote is not a green light, at least not yet

Now for the sober part, and our clients have heard me say this before: a favorable PCAC vote is necessary, but it is not sufficient. PCAC is an advisory committee. Under section 503A(b)(1)(A)(i)(III) of the Federal Food, Drug, and Cosmetic Act, the FDA is required to consult PCAC before it adds a bulk substance to the 503A list, but the statute does not hand the committee the pen. The FDA retains exclusive authority over the final decision, and it has declined to follow PCAC recommendations before.

On paper, the road from this week’s vote to a pharmacy lawfully compounding these peptides runs through five stages: FDA internal review (roughly three to twelve months), a notice of proposed rulemaking, a 60-to-90-day public comment period, a final rule, and finally an effective date. Historically, that full sequence, from a favorable vote to enforceable listing in 21 C.F.R. § 216.10, has taken two to four years, and sometimes longer. The final-rule stage alone has dragged on for years and has been the subject of litigation over the agency’s pace.

If you compound these peptides today on the strength of Thursday’s vote alone, you are compounding at your own enforcement risk. That has not changed.

The short-cut nobody is required to take, but the FDA could

Here is the part I want compounders and prescribers to understand, because it is where the conventional timeline and the political reality part ways.

The FDA does not have to make anyone wait two to four years. That multi-year rulemaking clock describes the formal, belt-and-suspenders path to permanent listing. It is not the only tool the agency has. The FDA can, and in my view should, short-cut the entire wait by simply adding the peptides that earned affirmative PCAC votes to the interim Category 1 bulk substances framework used for 503B outsourcing facilities, and by extending comparable enforcement discretion to 503A pharmacies while the formal rule works its way through the pipeline.

This is not a novel maneuver. The agency has used interim enforcement categories precisely to bridge the gap between a substance that is plainly headed for the list and the slow grind of notice-and-comment rulemaking. A Category 1 designation tells the field, in effect, that the FDA does not intend to pursue enforcement against outsourcing facilities compounding the substance while it finishes the paperwork. Pairing that with 503A enforcement discretion would give patients access now, give pharmacies a defensible compliance posture now, and cost the agency nothing it has not already signaled it is willing to do. The peptides that cleared PCAC this week are, by definition, the ones the agency’s own advisory process has flagged as appropriate candidates. There is no sound policy reason to make patients wait years for a conclusion the committee has already reached.

Whether the FDA will actually move that quickly is a separate question. This administration has been publicly supportive of expanding peptide access, which cuts in favor of speed. But the agency’s posture on compounding has been inconsistent before, and I would not counsel any client to bet the pharmacy on a favorable press release.

The bottom line, with healthy skepticism

This week was a genuine turning point, the first time in recent memory that a balanced PCAC looked at a slate of peptides and said yes. That matters. It shifts the political center of gravity, it strengthens the record for the rulemaking to come, and it hands the FDA every justification it needs to act quickly if it chooses to.

But a recommendation is still just a recommendation. I feel like there is a School House Rock episode in there to complement Bill’s story. Bill was only a bill sitting on capitol hill, but he hoped and prayed that someday he would become a law. Until the FDA either finalizes a rule or formally extends interim enforcement discretion, ideally through the Category 1 and 503A pathways described above, the prudent course for compounders is the same one it has always been: compound conservatively, document thoroughly, and resist the temptation to treat a committee’s endorsement as the agency’s authorization. We will be watching every step, and we will keep our clients out in front of it.

How Boesen & Snow Law can help

If you compound any of these peptides, or are weighing whether to, this is the moment to get your compliance posture in order rather than wait for the final rule. Our firm can help you evaluate what the PCAC votes and the FDA’s next steps actually mean for your operation, assess the enforcement and litigation risks specific to the substances you handle, and build a practical action plan covering API sourcing, documentation, and prescription and marketing practices. If you have questions about how any of this applies to your 503A pharmacy or 503B outsourcing facility, we are glad to talk them through.

t.